Current treatment recommendations and considerations for cryopyrin-associated periodic syndrome

References

• de Jesus AA, Canna SW, Liu Y, Goldbach-Mansky R. Molecular Mechanisms in Genetically Defined Autoinflammatory Diseases: Disorders of Amplified Danger Signaling. Annu Rev Immunol 2015;33:823-74
   PubMed Web of Science ®Google Scholar
• Martinon F, Burns K, Tschopp J. The inflammasome: a molecular platform triggering activation of inflammatory caspases and processing of proIL-beta. Mol Cell 2002;10:417-26
   PubMed Web of Science ®Google Scholar
• Agostini L, Martinon F, Burns K, et al. NALP3 forms an IL-1β-processing inflammasome with increased activity in Muckle-Wells autoinflammatory disorder. Immunity 2004;20:319-12
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Lowe P, Felix SD, et al. In vivo regulation of interleukin 1 beta in patients with cryopyrin-associated periodic syndromes. J Exp Med 2009;206(5):1029-36
   PubMed Web of Science ®Google Scholar
• Netea MG, Nold-Petry CA, Nold MF, et al. Differential requirement for the activation of the inflammasome for processing and release of IL-1β in monocytes and macrophages. Blood 2009;113:2324-35
   PubMed Web of Science ®Google Scholar
• Dinarello CA. Immunological and Inflammatory Functions of the Interleukin-1 Family. Annu Rev Immunol 2009 2009 27:519-50
   Google Scholar
• Haverkamp MH, van de Vosse E, Goldbach-Mansky R, Holland SM. Impaired cytokine responses in patients with cryopyrin-associated periodic syndrome (CAPS). Clin Exp Immunol 2014;177(3):720-31
   PubMed Web of Science ®Google Scholar
• Wanderer AA, Hoffman HM. The sprectrom of acquired and familial cold-induced urticarial/urticarial_like syndromes. Immunol Allergy Clin North Am 2004;24(2):259-86
   PubMed Web of Science ®Google Scholar
• Muckle TJ, Wells M. Urticaria, deafness, and amyloidosis: a new heredo-familial syndrome. Q J Med 1962;31:235-48
   PubMedGoogle Scholar
• Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and Muckle-Wells syndrome. Nat Genet 2001;29(3):301-5
   PubMed Web of Science ®Google Scholar
• Prieur AM, Griscelli C, Lampert F, et al. Chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. Scand J Rheumatol Suppl 1987;66:57-68
   PubMedGoogle Scholar
• Aksentijevich ID, Putnam C, Remmers EF, et al. The clinical continuum of cryopyrinopathies: Novel CIAS1 mutations in North American patients and a new cryopyrin model. Arthritis Rheum 2007;56(4):1273-85
   PubMed Web of Science ®Google Scholar
• Lepore L, Paloni G, Caorsi R, et al. Follow-up and quality of life of patients with cryopyrin-associated periodic syndromes treated with Anakinra. J Pediatr 2010;157(2):310-15
   PubMed Web of Science ®Google Scholar
• Levy R, Gérard L, Kuemmerle-Deschner J, et al. Phenotype and genotype of cryopyrin-associated periodic syndrome (CAPS: A series of 136 patients from the Eurofever international registry. Ann Rheum Dis 2014. [Epub ahead of print]
   Google Scholar
• Hawkins PN, Lachmann HJ, McDermott MF. Interleukin-1-receptor antagonist in the Muckle-Wells syndrome. N Engl J Med 2003;348(25):2583-4
   PubMed Web of Science ®Google Scholar
• Ter Haar N, Lachmann H, Ozen S, et al. Treatment of autoinflammatory diseases: results from the Eurofever Registry and a literature review. Ann Rheum Dis 2013;72:678-85
   PubMed Web of Science ®Google Scholar
• Hawkins PN, Lachmann HJ, Aganna E, McDermott MF. Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. Arthritis Rheum 2004;50:607-12
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Rosengren S, Boyle DL, et al. Prevention of cold-associated acute inflammation in familial cold autoinflammatory syndrome by interleukin-1 receptor antagonist. Lancet 2004;364:1779-85
   PubMed Web of Science ®Google Scholar
• Lovell DJ, Bowyer SL, Solinger AM. Interleukin-1 blockade by anakinra improves clinical symptoms in patients with neonatal onset multisystem inflammatory disease. Arthritis Rheum 2005;52:1283-6
   PubMed Web of Science ®Google Scholar
• Goldbach-Mansky R, Dailey NJ, Canna SW, et al. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1 inhibition. N.Eng J Med 2006;355:581-92
   PubMed Web of Science ®Google Scholar
• Leslie KS, Lachmann HJ, Bruning E, et al. Phenotype, genotype, and sustained response to anakinra in 22 patients with autoinflammatory disease associated with CIAS-1/NALP3 mutations. Arch Dermatol 2006;142:1591-7
   PubMed Web of Science ®Google Scholar
• Maksimovic L, Stirnemann J, Caux F, et al. New CIAS1 mutation and anakinra efficacy in overlapping of Muckle-Wells and familial cold autoinflammatory syndromes. Rheumatology (Oxford) 2008;47:309-10
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Tyrrell PN, Koetter I, et al. Efficacy and safety of anakinra therapy in pediatric and adult patients with the autoinflammatory Muckle-Wells syndrome. Arthritis Rheum 2011;63(3):840-9
   PubMed Web of Science ®Google Scholar
• Sibley CH, Plass N, Snow J, et al. Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes. Arthritis Rheum 2012;64(7):2375-86
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Kone-Paut I, Kuemmerle-Deschner JB, et al. Use of canakinumab in the cryopyrin-associated periodic syndrome. N Eng J Med 2009;360(23):2416-25
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies. Arthritis Rheum 2008;8(8):2443-52
   Web of Science ®Google Scholar
• Anakinra. Summary of product characteristics. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000363/WC500042310.pdf
   Google Scholar
• Neven B, Marvillet I, Terrada C, et al. Long-term efficacy of the interleukin-1 receptor antagonist anakinra in ten patients with neonatal-onset multisystem inflammatory disease/chronic infantile neurologic, cutaneous, articular syndrome. Arthritis Rheum 2010;62(1):258-66
   PubMed Web of Science ®Google Scholar
• Canakinumab: Summary of product characteristics. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001109/WC500031680.pdf
   Google Scholar
• Koné-Paut I, Galeotti C. Anakinra for cryopyrin -associated periodic syndrome. Expert Rev Clin Immunol 2014;10(1):7-18
   PubMed Web of Science ®Google Scholar
• Miyamae T, Inaba Y, Nishimura G, et al. Effect of anakinra on arthropathy in CINCA/NOMID syndrome. Yokokta S. Pediatr Rheumatol Online J 2010;16:8-9
   Google Scholar
• Berthet G, Von Scheven-Gête A, et al. Neonatal treatment of CINCA syndrome. Pediatr Rheumatol Online J 2014;12(1):52
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Hachulla E, Cartwright R, et al. Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes. Ann Rheum Dis 2011;70(12):2095-102
   PubMed Web of Science ®Google Scholar
• Sibley CH, Chioato A, Felix S, et al. A 24-month open-label study of canakinumab in neonatal-onset multisystem inflammatory disease. Ann Rheum Dis 2014. [Epub ahead of print]
   PubMed Web of Science ®Google Scholar
• Kone-Paut I, Lachmann HJ, Kuemmerle-Deschner JB, et al. Sustained remission of symptoms and improved health-related quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab: results of a double-blind placebo-controlled randomized withdrawal study. Arthritis Res Ther 2011;13(6):R202
   PubMed Web of Science ®Google Scholar
• Marsaud C, Marie I, Koné-Paut I. Long term follow-up of quality of life in patients with cryopyrin-associated periodic syndrome treated with canakinumab, an anti-interleukin 1β monoclonal antibody. J Rheumatol 2014;41(8):1721-2
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Throne ML, Amar NJ, et al. Long-term efficacy and safety profile of rilonacept in the treatment of cryopryin-associated periodic syndromes: results of a 72-week open-label extension study. Clin Ther 2012;34(10):2091-103
   PubMed Web of Science ®Google Scholar
• Olivecrona H, Alden Raboisson M, Söderberg M, et al. Kineret © (anakinra) controls severe disease symptoms in patients with severe disease symptoms in patients with severe Cryopyrin-associated periodic syndrome (CAPS): Up to 5 years follow-up data. Ann Rheum Dis 2013;72(Suppl 3):70-1
   Google Scholar
• Rossi-Semerano L, Fautrel B, Wendling D, et al. Tolerance and efficacy of off-label anti-interleukin-1 treatments in France: a nationwide survey. Orphanet. Journal Rare Diseases 2015;10(1):19
   PubMed Web of Science ®Google Scholar
• Chang Z, Spong C, Jesus AA, et al. Anakinra use during pregnancy in patients with cryopyrin-associated periodic syndromes (CAPS). Arthritis Rheumatol 2014. [Epub ahead of print]
   Google Scholar
• Hoffman HM, Kuemmerle-Deschner JB, Hawkins PN, et al. Canakinumab use in patients with cryopyrin-associated periodic syndrome: interim safety and efficacy results from beta-confident registry. Arthritis & Rheumatology 2014;66:S367
   Google Scholar
• Rilonacept: Summary of product characteristics. Available from: www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001047/WC500026510.pdf
   Google Scholar
• Cuisset L, Jeru I, Dumont B, et al. Mutations in the autoinflammatory cryopyrin-associated periodic syndrome gene: epidemiological study and lessons from eight years of genetic analysis in France. Ann Rheum Dis 2011;70(3):495-9
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Lohse P, Koetter I, et al. NLRP3 E311K mutation in a large family with Muckle-Wells syndrome-description of a heterogeneous phenotype and response to treatment. Arthritis Res Ther 2011;13(6):R196
   PubMed Web of Science ®Google Scholar
• Lachmann HJ, Goodman HJ, Gilbertson JA, et al. Natural history and outcome in systemic AA amyloidosis. N Eng J Med 2007;356(23):2361-71
   PubMed Web of Science ®Google Scholar
• Piram M, Koné-Paut I, Lachmann HJ, et al. Validation of the auto-inflammatory diseases activity index (AIDAI) for hereditary recurrent fever syndromes. Ann Rheum Dis 2014;73(12):2168-73
   PubMed Web of Science ®Google Scholar
• Kanariou M, Tantou S, Varela I, et al. Successful management of cryopyrin-associated periodic syndrome with canakinumab in infancy. Pediatrics 2014;134:5
   PubMed Web of Science ®Google Scholar
• Kuemmerle-Deschner JB, Wittkowski H, Tyrrell PN, et al. Treatment of Muckle-Wells syndrome: analysis of two IL-1-blocking regimens. Arthritis Res Ther 2013;15(3):R64
   PubMed Web of Science ®Google Scholar
• Terrada C, Neven B, Boddaert N, et al. Ocular modifications in a young girl with cryopyrin-associated periodic syndromes responding to interleukin-1 receptor antagonist anakinra. J Ophtalmic Inflamm Infect 2001;1(3):133-6
   Google Scholar
• Scarpioni R, Rigante D, Cantarini L, et al. Renal involvement in secondary amyloidosis of Muckle-Wells syndrome: marked improvement of renal function and reduction of proteinuria after therapy with human anti-interleukin-1β monoclonal antibody canakinumab.Clin Rheumatol. 2014. [Epub ahead of print]
   Google Scholar
• Tran TA, Koné-Paut I, Marie I, et al. Muckle-Wells syndrome and male hypofertility: a case series. Semin Arthritis Rheum 2012;42(3):327-31
   PubMed Web of Science ®Google Scholar
• Available from: www.printo.it/eurofever/
   Google Scholar
• Clinical outcomes and safety: a registry study of Ilaris (Canakinumab) patients (B-Confident). Available from: https://clinicaltrials.gov/ct2/show/NCT01213641
   Google Scholar